Trial Profile
A Phase II Study of Rucaparib Monotherapy in Nonmetastatic, Hormone-Sensitive Prostate Cancer Demonstrating "BRCAness" Genotype (ROAR)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 29 Jun 2023
Price :
$35
*
At a glance
- Drugs Rucaparib (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- Acronyms ROAR
- 23 Jun 2023 Planned End Date changed from 1 Jul 2023 to 12 Jan 2024.
- 18 Feb 2023 Status changed from active, no longer recruiting to discontinued.
- 18 Feb 2023 Results(n=7)hypothesizing that treatment with rucaparib monotherapy in men with systemic treatment naive high-risk nmHSPC would result in acceptable disease control, allow a delay of androgen deprivation therapy (ADT) and the onset of metastasis presented at the 2023 Genitourinary Cancers Symposium